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 I 
SUMMARY 
 
The elongation factor 1A has a crucial role in protein biosynthesis. EF1A 
belongs to the GTP-binding family of proteins and is able to deliver the aa-
tRNA to the A-site of the ribosome because of its GTPase activity. Higher 
eukaryotes express two tissue specific isoforms of EF1A. In the last years, 
these isoforms were found to be involved in several different processes  like 
senescence, apoptosis and transformation. In particular EF1A2 is 
overexpressed in several tumor cells and participates in drug resistence 
processes. Previous experiments in H1355 cells demonstrated that IFN 
treatment results in an antiapoptotical answer during which EF1A2 is 
increasingly expressed due to its RAF kinase mediated phosphorylation. As 
this interaction establishes a new link between the mitogenic cascade and 
protein biosynthesis, in vitro kinase assays were performed in presence of 
B- and C-RAF kinase and recombinant EF1A1/2 to investigate this 
important interaction. Mass spectrometry analysis identified treonine 88 
(exclusively mediated by B-RAF) and serine 21 on EF1A1 and serine 21 on 
EF1A2 as  B-/ and C-RAF mediated phosphorylation sites. Interestingly, 
serine 21 belongs to the consensus sequence of the GTP/GDP binding 
domain of EF1A. Its phosphorylation prevents the binding of  the nucleotide 
suggesting that this potentially RAF mediated modification has a regulatory 
role affecting the function of the elongation factor. Moreover, the C-RAF 
mediated phosphorylation on S21 is enhanced when both isoforms were 
incubated together prior to the kinase/phosphorylation reaction. This 
suggests that the heterodimerization of the two isoforms results in a 
 II 
conformational change which increases the accessibility of serine 21 and 
thus supports the phosphorylation on this residue. Overexpression of EF1A1 
in proliferating COS 7 cells and mass spectrometry analysis followed by 
pull-down of GST-EF1A1 confirmed the phosphorylation of T88 in vivo. 
This indicates that B-RAF is directly implicated in the protein biosynthesis 
process. Further, generated mutants of EF1A1 (T88A/D and S21A/D) and 
EF1A2 (S21A/D) were overexpressed in COS 7 cells. In comparison to the 
wt, the S21A/D mutants were less stable and more rapidly degraded in a 
proteasome dependent manner. This demonstrates that S21 is an essential 
site for the activity of EF1A.  Taken together, the RAF mediated regulation 
of this site could be a crucial mechanism involved in the functional 
switching of EF1A between its role in protein biosynthesis and its 
participation in several other cellular processes, including drug resistance 
and transformation.  
 
 
 
 
 
 
 
 
 
 
 
 
 III 
RIASSUNTO 
 
Il fattore di allungamento 1A possiede un ruolo primario nella biosintesi 
delle proteine essendo artefice del corretto posizionamento dell’ aa-tRNA 
sul ribosoma. Questa funzione ed il suo corretto svolgimento sono garantite 
dall’attività GTPasica dello stesso fattore, il quale infatti appartiene alla 
famiglia delle GTP binding protein. EF1A negli organismi eucariotici 
superiori è presente in due isoforme (EF1A1 ed EF1A2) tessuto specifiche e 
negli ultimi anni è stato riscontrato il loro coinvolgimento in diversi processi 
cellulari quali senescenza, apoptosi e trasformazione. In particolare 
l’isoforma 2 risulta overespressa durante diversi tipi di tumore e partecipa a 
fenomeni di resistenza ai chemioterapici. Infatti, risultati precedenti hanno 
messo in luce che in un sistema cellulare di carcinoma epidermoide 
polmonare umano (H1355), il trattamento con INF induce una risposta 
antiapoptotica mediata dalle chinasi RAF ed esplicitata tramite 
overespressione e fosforilazione  maggiormente a carico di EF1A2.  In 
questo lavoro abbiamo cercato di chiarire la natura dell’interazione 
verificata tra il fattore di allungamento e le RAF chinasi ed il ruolo 
funzionale di questa interazione in vivo. Saggi di fosforilazione in vitro in 
presenza di RAF chinasi (B/C-RAF) e analisi di spettrometria di massa 
hanno rivelato la presenza di gruppi fosfato su entrambe le isoforme, in 
particolare i siti coinvolti nella modificazione risultano essere la treonina 88 
(mediata esclusivamente da B-RAF) e la serina 21 per EF1A1 e la serina 21 
per EF1A2. Da sottolineare che la serina 21 appartiene alla prima sequenza 
di consenso per il legame al GTP/GDP. Quando entrambe le isoforme sono 
 IV 
preincubate e successivamente saggiate in un saggio di chinasi in vitro la 
fosforilazione  ad opera di C-RAF sembra essere favorita suggerendo un 
eterodimerizzazione di EF1A che consente una maggiore disponibilità dei 
siti in S21 per entrambe le isoforme. Overespressione di EF1A1 in cellule 
COS 7 in attiva proliferazione ha confermato la fosforilazione in T88 
suggerendo il coinvolgimento diretto della chinasi B-RAF durante il 
processo di sintesi proteica. Inoltre, overespressione in COS 7 di entrambe 
le isoforme wt e mutate per i siti di fosforilazione ha rivelato una minore 
stabilità dei mutanti S21A/D rispetto al wt e ai mutanti  T88A/D. I risultati 
ottenuti suggeriscono che la fosforilazione in serina 21 faccia parte di un 
sistema regolatorio delle funzioni di EF1A mediato dalle RAF chinasi che 
potrebbe spiegare lo switch del fattore tra il suo ruolo nella sintesi proteica e 
quello in altri processi cellulari (legame all’F-actina,  organizzazione del 
citoscheletro, etc.) coinvolti nella tumorigenesi e nella resistenza ai 
chemioterapici.  
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            1 INTRODUCTION 
 
1.1 The eukaryotic elongation factor 1A (eEF1A) 
eEF1A is the second most abundant protein in the cell. It belongs to the 
GTP-binding elongation factor family and promotes the GTP-dependent 
binding of aminoacyl-tRNA (aa-tRNA) to the A-site of the ribosome during 
the elongation cycle in protein biosynthesis. Moreover, the GTPase activity 
of eEF1A is also used to enhance the accuracy of codon recognition. The 
functions of the elongation factor 1A in the elongation cycle have been 
extensively investigated in eubacteria, e. g. E.Coli (EF Tu) as well as in 
archaea e.g. Sulfolobus Sulfataricus (Krab I.M. et al., 1998; Arcari P. et al., 
1994) and eukaryotes, e. g. Saccharomyces cerevisiae. These studies 
showed the high conservation of the elongation factor between the three 
kingdoms as a well as among a wide range of different species underlining 
the importance of this protein for the life. 
 
1.1.1 Role in protein biosynthesis: the elongation factor 1 
complex  
 
The protein biosynthesis is a process present in all organisms, prokaryotes 
and eukaryotes, sharing a similar mechanisms. It starts from the ribosome 
and involves four different stages: initiation, elongation, termination and 
recycling (Noble, et al., 2008). All of these steps are tightly controlled by 
specific translation factors. Many of these proteins are GTPases, which are 
activated by binding to the  ribosome, on a site called the GTPase-activating 
center (GAC) (Ramakrishnan et al., 2002). In eukaryotes, at the initiation 
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point, the 40S ribosomal subunit is bound by a ternary complex consisting 
of the initiation factor 2 (eIF2), GTP and methionyl initiator tRNA (Met-
tRNAi) to form the 43S complex. The recruitment of mRNA is due to the 
eIF4 that, together with the poly(A)-binding protein (PABP), recognise the 
5’-terminal cap or the 3’-terminal poly(A) tract of mRNA. The mRNA will 
be transferred to the 43S complex resulting in the 48S complex. Once the 
first AUG in good sequence context has been found, the initiation factors 
are replaced by the 60S subunit to form the 80S initiation complex, via GTP 
hydrolysis on eIF2 mediated by eIF5 (Rhoads et al.,2006). Now the 
complex is ready to recive the first elongator tRNA and to start with the 
elongation stage of the biosynthesis. In higher eukaryotes the elongation 
factors work always as a complex, the elongation factor 1 complex, 
consisting of eEF1A and the three subunit of eEF1B (Sonenberg, et al. 
2000) 
 
 
 
Fig. 1.1 Initiation cycle in eukaryots : to complete the initiation cycle, the hydrolysis of 
the GTP bound to eIF2 is required. released eIF2-GDP is than recycled to eIF2-GTP by the 
guanine nucleotide exchange eIF2B. Fig.s adapted from Rhoads R.E. et al.  
 
The elongation phase of protein synthesis is a cyclic process consisting of 
basic steps repeated until the entire coding sequence of the mRNA is 
translated and a termination codon come out in the decoding site. During 
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elongation, the active form of the elongation factor 1A binds the GTP and 
transports the new aminoacyl-tRNA (aa-tRNA), as a ternary complex (Fig. 
1.2), to the empty A site of the 80S initiation complex (Stark et al., 1997). 
In particular, eEF1A-GTP protects the aa-tRNA against hydrolysis and 
assists the ribosome in making a correct interaction between the current 
codon on the mRNA and the anticodon of the transported aa-tRNA (Pape et 
al., 1999). Such a decoding event triggers the ribosome to induce GTP 
hydrolysis on eEF1A (Nilsson, et al., 2005) and leads its major 
conformational change, which causes the release of aa-tRNA and the 
accommodation of the 3’ end in the PT (peptidyl transferase) centre on the 
60S subunit, followed by peptide-bond formation (Nissen, et al., 2000). In 
parallel,  the inactive GDP-bound eEF1A is released from the ribosome. 
This inactive form of eEF1A, unable to bind another aa-tRNA, is recycled 
on the active form by the elongation factor 1B (eEF1B). eEF1B consists of 
three subunits  and and works as a guanine nucleotide-exchange factor 
(GEF) for eEF1A (Andersen, et al., 2001; Andersen, et al. 2003). In the 
following step, elongation factor 2 (eEF2) catalyzes the translocation of A 
and P site tRNAs to the P and E sites respectively, as well as movement of 
the mRNA by exactly one codon to allow a new round of elongation 
(Rodnina, et al., 1997). A-site-bound aa-tRNA reacts with P-site-bound 
pept-tRNA (peptidyltRNA) to form a peptide bond, resulting in deacylated 
tRNA in the P site and pept-tRNA prolonged by one amino acid in the A 
site.  
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Fig. 1.2 Elongation cycle in eukaryots: crucial step in the elongation stage is the selection 
of the correct aa-tRNA, based on codon-anticodon interaction. The ribosome supervises this 
point during an initial selection of the ternary complex and during proofreading of the aa-
tRNA. The initial selection utilizes the ability of cognate tRNA to stimulate the GTPase 
activity of eEF1A much faster than non-cognate and near-cognate tRNA.   
 
When the ribosome come across one of the stop codons, UAA,UAG or 
UGA, release factor 1 (eRF1) is recruited to the ribosome to promote the 
release of the newly synthesized polypeptide from the ribosome. After 
termination, the ribosome dissociates into its constituent subunits and the 
mRNA and deacylated tRNA are released, allowing the ribosome to be 
recycled, by release factor 3 (eRF3) in cooperation with eEF2 (Noble, et al., 
2008). 
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1.1.2 Structures and isoforms  
 
Thanks to the recent development in macromolecular crystallography and 
cryo-electron microscopy, huge progress has been made in structure 
determination of components of the translation machinery, including atomic 
structures of many translation factors and both subunits of the bacterial 
ribosome. In particular several structural results have been obtaneid about 
the prokaryotic homolog of eEF1A, EF-Tu. Crystal structures of full-length 
EF-Tu from Thermus Thermophilus, Thermus Aquaticus and Escerichia 
Coli were solved in complex with the non-hydrolyzable GTP analogue and 
with bound GDP (Berchtold, et al.,1993; Kjeldgaard, et al., 1993; Polekhina 
et al., 1996; Abel, et al., 1996). 
 
Fig. 1.3 Solved structures of EF-Tu: A) Crystal structure of full-length EF-Tu from T. 
Acquaticus in complex with the non-hydrolysable GTP analogue, B) EF-Tu from E. Coli in 
complex with GDP. The three domains of EF-Tu are in red, green and blue, respectively; 
nucleotides are represented in stick model, whereas Mg2+ ion as grey ball. In yellow the 
switch regions. 
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These structures showed clearly that EF-Tu consists of three domains. The 
GTP binding domain, domain I or the G domain, has the same basic 
structure compared to the GTPase domains of other G proteins. Domains II 
and III are both consisting of  barrels and, in all known structures, are in 
the same relative orientation,  suggesting that they function as a single rigid 
unit. Moreover, EF-Tu shows a large conformational change upon 
hydrolysis of GTP to GDP, that causes a substantial rotation of the G 
domain with respect to domains II and III and a switch of a specific region 
in the same domain. Co-crystal structure of yeast eEF1A bound with the 
guanilic  nucleotide offer a detailed overview on the guanine binding 
domain in eukaryotes. This confirms, together with a solved structure of an 
archeal GDP bound EF1A (REF), a well conserved folding of the protein 
among different species. Although eEF1A contains additional inserts within 
the G domain. Interestingly, the consensus sequences of the GTP/GDP 
binding site are identical for all of them (Fig. 1.4). Structures have also been 
solved for EF-Tu bound to EF-Ts, facilitating to understand how EF-Ts 
catalyzes the exchange of GDP to GTP. EF-Ts binds between the G domain 
and domains I and II and weakens the affinity of EF-Tu for the GDP by 
altering the GDP-binding pocket. This allows GDP to dissociate and the 
rebinding of GTP. The structures of prokaryotic EF-Tu and the homologous 
eukaryotic elongation factor, eEF1A, are very similar, although eEF1A 
contains additional inserts within the G domain. Therefore it was surprising 
to find that the GEF for eEF1A, eEF1B, works by a different mechanism 
from that of EF-Ts. The crystal structure of eEF1A bound to the catalytic 
domain of eEF1B showed that eEF1B bound to eEF1A in an entirely 
different manner. E. g. Mg
2+
 does not appear to be required for the exchange 
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mechanism, in contrast to EF-Tu, since the structure of archaeal EF1A 
indicated that the GDP-bound form of eEF1A no longer coordinates Mg
2+
 in 
the nucleotide-binding site, suggesting that eEF1B induces local 
conformational changes that cause GDP dissociation. It is also thought that 
eEF1B prevents the binding of eEF1A to an aa-tRNA, thus preventing it 
from forming a ternary complex until GTP is rebound. 
In higher vertebrates, eEF1A is found in two variant forms, encoded by 
distinct genes (Lund et al., 1996), and with different expression patterns. 
The near-ubiquitous form, eEF1A1, is expressed in all tissues throughout 
development but is absent in adult muscle and heart (Lee et al., 1992; 
Chambers et al., 1998). The latter tissues express instead eEF1A2 as do 
certain other cell types including, notably, large motor neurons, islet cells in 
the pancreas and enteroendocrine cells in the gut (Newbery et al., 2007). 
Despite sharing 92% sequence identity (Fig. 1.4), paralogous human 
eEF1A1 and eEF1A2 have different functional profiles. 
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Fig. 1.4 Multiple sequence alignment of elongation factor 1 from different organisms: 
The alignment was performed using the aminoacidic sequences of the elongation factor 1 A 
(UniProtKB) from Sulfolobus Sulfataricus (SULSO), Escherichia Coli (ECOLI), Yeast 
(YEAST) and Human. Two variants of EF1A are present for Human (EF1A1 and EF1A2, 
see later in the text for explanations) in dark grey the identical conserved sites; in light grey 
or white conservatively substituted or not conserved. In green the GTP/GDP binding sites 
highly conserved.  
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They exhibit similar translation activities, but have different relative 
affinities for GTP and GDP (Kahns et al.,1998). eEF1A1 binds GTP more 
strongly than GDP, whereas the opposite is the case for eEF1A2. The GDP 
dissociation rate constant is seven-fold higher for eEF1A1 than for eEF1A2, 
and the GDP/GTP preference ratio is 0.82 for eEF1A1, but 1.50 for 
eEF1A2. Surprisingly, since this would predict its greater reliance on GTP-
exchange factors, eEF1A2 appears to show little or no affinity for the 
components of the guanine-nucleotide exchange factor (GEF) complex 
eEF1B in yeast-two-hybrid experiments (Mansilla et al., 2002). Moreover, 
from the pair-wise sequence alignment between the two human variants 
(Fig. 1.4), it is apparent that many of the changes involve substitution of Ser 
or Thr (total of 11); although no Tyr amino acid residues are lost or gained. 
 
1.1.3 Regulation of the elongation cycle in protein biosynthesis 
 
In the last several years the importance of translational control in cell 
growth, proliferation, development as well as survival, learning and memory 
has been underlined by the elucidation of the signalling intermediates 
involved in protein synthesis. The most important pathways  in eukaryots 
that control the translation apparatus are the PI3K/Akt/mTOR and the Ras-
MAPK signalling cascades (Sonenberg et al., 2007). In particular they 
phosphorylate the translation factors directly, like mTOR with 4E-BPs and 
S6 kinase and indirectly eIF4E and eIF4G. The Ras-MAPK pathway 
executes the phosphorylation of eIF4E and eIF4B. Usually this modification 
results in increased translation rates and cell growth/proliferation. So far the 
better understood mechanisms of translational control involved the initiation 
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factors (2, 2B, 4B, 4E e 4G), the elongation factor 2 and the ribosomal 
protein (rp) S6. Less is known about the regulation of eEF1A and eEF1B 
even though several groups have studied the phosphorylation and regulation 
of these two factors (Browne et al., 2002). In the following are summarized 
current knowledges. The casein kinase 2 (CK2) phosphorylates the  
subunit of eEF1B in vitro (Sheue et al., 1999) leading to an hypothetical less 
ability of the complete eEF1B to interacts  with eEF1A. Insulin or phorbol 
esters are able to enhance the phosphorylation of eEF1A, eEF1B and 
eEF1Bin vivo (Venema et al., 1991). From experimental results, which 
include phosphopetide mapping data, is possible to suggest the involvement 
of the protein kinase MS6K (multipotential S6 kinase) for all of them and 
further the activity of not-identified insulin-stimulated kinases for eEF1A. 
Anyway, phosphorylation of eEF1A/B  in vitro by MS6K result in a modest 
stimulation of its activity (Chang et el.,1997). eEF1A and eEF1B are also 
substrates for phosphorylation by the classical protein kinase C (PKC) 
isoforms in vitro and this may explain the ability of phorbol esters (which 
activate several PKCs) to increase the phosphorylation of these proteins in 
vivo (Venema et al., 1991). More precisely, PKC d phosphorylates eEF1A 
at Threonine 431 (based on murine sequence, Kielbassa et al., 1995). 
Phorbol esters also increase the phosphorylation of the valyl-tRNA 
synthetase that associates with eEF1A/B. The available evidence suggests 
that phosphorylation of eEF1A/B and of valyl-tRNA synthetase by PKC 
increases their activities in translation elongation and amino acylation, 
respectively. The increased activity of eEF1A/B appears to result from 
enhanced GEF activity. Lastly, in Xenopus oocytes, eEF1B is 
phosphorylated during meiotic maturation (Belle et al., 1989). It appears to 
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be a direct substrate for the protein kinase activity of the maturation-
promoting complex MPF (Janssen et al.,1991) and the major site of 
phosphorylation was identified as Thr230, which is conserved residues in 
mammals. The kinase present in MPF, cdc2, also phosphorylates eEF1B, 
in this case at Thr122 (Mulner-Lorillon et al.,1994). Although protein 
synthesis is increased during maturation, there is so far no evidence that 
these phosphorylation events actually alter the activity of eEF1A/eEF1B. 
 
Fig. 1. 5 Phosphorylation sites on eukaryotic elongation factors.  
The Fig. describe the residues involved as substrate for identified kinases on the elongation 
factors.  
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1.1.4 The eukaryotic elongation factor 1A in different biological 
process 
 
eEF1A1 has been shown to be involved  in additional non-canonical 
functions, including actin-binding and bundling, apoptosis, nuclear 
transport, proteasomal-mediated degradation of damaged proteins, heat 
shock and transformation. eEF1A2 has been less extensively studied at the 
biochemical level, so it is not yet clear how many of these non-canonical 
functions are shared by this variant. For example, eEF1A2 has been shown 
to have a role in actin remodeling in cells (Jeghanathan et al., 2008), but has 
not been shown directly to bind to actin. In humans, eEF1A2 has been 
shown to have oncogenic properties when inappropriately overexpressed, 
and has been implicated in ovarian, breast, pancreatic, liver and lung cancer 
(ref putative oncogene), although the mechanism for overexpression 
remains elusive, and no mutations have been identified in ovarian tumors 
(Tomlinson et al., 2007). Loss of expression of eEF1A2, on the other hand, 
has been shown in mice to result in motor neuron degeneration reminiscent 
of motor neuron disease, or amyotrophic lateral sclerosis (Chambers et al., 
1998). How eEF1A2 isoform is involved in malignant transformation is not 
as yet understood. Since tyrosine kinases are prominent players in cancer 
development, direct comparison of the ability of eEF1A1 and eEF1A2 to be 
involved in phospho Tyr-specific signalling processes could help to interpret 
cancer-related properties of eEF1A2. Large-scale proteomics studies 
(Molina, et al., 2007) revealed that conserved Tyr residues (Tyr29, Tyr85, 
Tyr86, Tyr141, Tyr162, Tyr254) in both human eEF1A variants are 
phosphorylated (Fig. 1.6). 
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Fig. 1.6 Functional domains and phosphorylation sites of eEF1A1/2: eEF1A binds 
GDP/GTP through three different binding sites (aa 14-21, blue box; aa 91-95, green box; aa 
153-156, violett box). As indicated, the consensus sequences of these sites are conserved 
between the two isoforms (eEF1A1, black; eEF1A2, yellow). Albeit both isoforms share a 
sequence homology of 98%, only eEF1A1 is phosphorylated on Y86 and Y162 in addition 
to the conserved phosphorylation sites Y29 and Y141 of eEF1A1 and eEF1A2.  
 
 
1.2 The mitogenic cascade and RAF kinases 
 
The discovery of the transforming activity of the viral oncogene v-RAF (an 
oncogenic product of the murine sarcoma virus 3611; Rapp et al., 1983) was 
the basic finding to understand the control of proliferation, cell growth, 
survival and differentiation via extracellular stimuli (e. g. growth factors). 
The family of RAF kinases are serine/threonine kinases that exhibit 
important roles in the regulation of the highly conserved RAS RAS-RAF 
RAF-MEK MEK-ERK cascade. In mammalian cells three isoforms of RAF 
kinases exist, called A-RAF, B-RAF and C-RAF. As C-RAF was the first 
kinase descirbed to induce tumors in prior healthy organisms (Rapp et al., 
1983), nowadays B-RAF gained much attention because of its role in cancer 
progression. This isoform carries a cancer relevant mutation (valin at 
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position 600 is mutated to glutamate; Fig. 1.7) which is found in several 
cancer types, e. g. melanoma or colorectal carcinoma (Davies et al., 2002).  
 
 
 
Fig. 1.7: Cancer relevant mutations in B-RAF  
Mutations of B-RAF that are relevant in human cancer are present in the glycin – rich loop 
and the activation segment (corresponding sequences are aligned to A-/ C-RAF as indicated 
in boxes).  
 
Whereas B- as well as C-RAF play a role in cancer, the relevance of A-RAF 
in this field is unclear. However, tissue specific expression levels of all three 
isoforms were found by Storm and co-workers (Storm et al., 1990). 
Remarkably, B-RAF is mainly expressed on higher levels in the nervous 
system, whereas the highest C-RAF levels are found in striated muscle, 
cerebellum and fetal brain. A-RAF is found in high amounts in urogenital 
organs (Luckett et al., 2000). Independently from their tissue specific 
expression, all isoforms activate the downstream cascade, but differ in their 
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individual function. Knocking out RAF proteins in mice, Pritchard and other 
colleagues showed (Pritchard et al., 1996; Wojnowski et al. 1997; Mikula et 
al. 2001; Huser et al. 2001), that each RAF isoform has a distinct function in 
development. A-RAF -/- embryos are for example viable, but show 
neurological and intestinal disorders, whereas C- as well as B-RAF embryos 
die early in development (Pritchard et al., 1996). The latter embryos show 
vascular defects and die because of vascular haemorrhage. This is 
accompanied by overall growth retardation and increased apoptosis in 
endothelial tissues (Wojnowski et al., 1997). C-RAF -/- embryos were small 
in size and death was caused by a high apoptosis rate in the liver. 
Furthermore, these embryos died during midgestation and showed poor 
development of the placenta and especially of the liver and the 
haematopoietic compartment (Mikula et al., 2001; Huser et al., 2001). 
Taken together, these findings indicate, that RAF signalling is crucial for 
cellular processes like proliferation, development and differentiation, 
whereas its deregulation can also lead to cell transformation (Leicht et al. 
2007). Investigating the functions of the mitogenic cascade, these Ras 
connected serine/threonine kinases were found to activate further 
downstream kinases (MEK, ERK), transmitting the signal into the nucleus. 
As shown in Fig. 1.8, the binding of growth factors activates via an 
exchange of a guanidine nucleotide Ras that binds to the Ras-binding-
domain (RBD) of RAF (Wittinghofer et al., 1996). Besides this RBD 
dependent interaction, RAS also binds to the cysteine rich domain (CRD) of 
RAF (Hancock et al., 2003). This, from the GTP status of RAS independent 
process, recruits RAF to the plasma membrane. Although this interaction 
does not boost the kinase activity, it initializes the activation of RAF. 
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Activated RAF phosphorylates its downstream target MEK (MEK 1: 
S217/S221) further activating ERK on threonine and tyrosine residues (ERK 
1: T202/Y204). Finally, activated ERK is able to mediate this extracellular 
response and targets multiple cytosolic, but also nuclear effector molecules. 
ERK can shuttle inside the nucleus, where it phophorylates and regulates 
several transcription factors, particularly myc, Elk1, p53, Ets1/2 and the AP 
AP-1 complex that comprises various heterodimers of c c-fos and c c-jun 
family members (Treisman, 1996; Adhikary and Eilers, 2007; Gille et al., 
1992; Milne et al., 1994; Yang et al., 1996; Buchwalter et al. 2004; 
Balmanno and Cook, 1999; Shaulian and Karin, 2002). The biological 
consequences of this mitogenic signalling cascade depend on signal 
intensity as well as signal duration. As shown in fibroblasts, induction of 
proliferation with platelet-derived-growth-factor (PDGF) depends on 
continuing ERK activity, whereas strong RAF signalling results in a cell 
cycle arrest due to the transcription of cell cycle inhibitors such as p21 
(Woods et al., 1997; Kerkhoff et al., 1998).  
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Fig. 1.8: Schematic representation of the mitogenic cascade 
Growth factor binding to the receptor tyrosine kinase results in the dimerization of the 
receptor, activating the Grb2/Sos2 complex further activating Ras via GDP/GTP exchange. 
RAS mediated membrane recruitment of RAF activates this kinase. Active RAF 
phosphorlyates ist downstream kinase MEK that further phosphorylates ERK. Downstream 
substrates of ERK are either cytoplasmatic or nuclear. The stabilization and coordination of 
the cascade is supported by scaffodling proteins. These scaffodling proteins directly 
regulate the efficiency of the activation process as well as the maintanance of the signal.      
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1.3 Scientific hypothesis and aim of the work 
 
Interferes a potential direct interaction between RAF kinase(s) and the 
elongation factor 1A with the regulation of protein biosynthesis? 
 
Protein biosynthesis is a fundamental process in the evolution and 
maintenance of life. Considering the huge biodiversity on our planet, it is 
intriguing that molecules participating in this process are found to be 
conserved from some of the earliest single cell organisms, e. g. 
Archeabacteria to the most recent species - humans. Regarding the 
development of a differentiated multicellular organism, cellular proliferation 
is an essential step that requires proteinbiosynthesis to fullfill the need for 
elevated levels of macromolecules. A recent finding connects both of these 
necessary events via two molecules: the proliferation as well as other cell 
process affecting incidences (e. g. transformation) regulating kinase RAF 
and the elongation factor 1A that plays a central role in the translational 
elongation as well as several other processes (e. g. apoptosis) (Lamberti et 
al., 2007). Until today, it is not entirely clear, which RAF isoforms (A-, B-, 
or C - RAF) can directly interact with EF1A and how this potential RAF 
mediated phosphorlyation of EF1A affects the elongation factor itself. 
Keeping in mind, that both proteins are overexpressed (mutated) in several 
kinds of cancer, a potential direct interaction that affects the protein 
biosynthesis rate and subsequently accelerates cellular proliferation is 
plausible. First aim of this work was to identify RAF isofom(s) that directly 
phosphorylate EF1A. The identification of residues on EF1A, that are 
targeted by RAF, further allows to characterise the subsequent outcome of 
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this direct interaction on molecular level. Studying the underlying 
mechanism of a potential RAF mediated regulation of EF1A also links the 
activity of one of the most cancer relevant proteins to a fundamental process 
in the cell. This connection could shed light on a so far unknown interaction 
between two of the most important events during the life of (multi-) cellular 
organisms as well as cancer - cellular proliferation and protein biosynthesis.     
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2 MATERIALS AND METHODS  
 
2.1 Materials  
 
2.1.1 Working with bacteria 
Instruments:  
Bacterial incubator (Heraeus B 6200), Bacterial shaker (New Brunswick 
Scientific innova 4330), Centrifuge RC 5B plus (Sorvall), Thermocycler 
(PeqLab), Thermomixer (Eppendorf), NanoDrop (Thermo). 
 
Chemicals: 
Ampicillin (SIGMA), Bacto-Agar (DIFCO), Bacto-tryptone (Roth), Sodium 
Chloride (AppliChem), Yeast extract (DIFCO), IPTG, Isopropyl β-D-
thiogalactoside (SIGMA), Ni-IDA (Macherey&Nagel), PMSF (Fluka). 
ATP, ADP (SIGMA), ]32ATP (Hartmann Analytics), Magnesiumchloride 
(AppliChem). 
 
Enzymes and Oligonucleotides: 
Polymerase (NEB), Pfu polymerase (Stratagene), T4 Ligase (Fermentas), 
Oligonucleotides (Metabion), dNTPs (Fermentas). 
 
Constructs: 
pET30a-EF1A1-(His)5  (MSZ institute) 
Pet22-EF1A2-(His)6 (Lamberti et al.) 
pcDNA3.1-(His)6-EF1A1 (this work) 
pcDNA3.1-(His)6-EF1A2 (Knudsen et al.) 
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pEBG-GST-EF1A1(this work) 
pEBG-GST-EF1A1 T88A/D (this work) 
pEBG-GST-EF1A1 S21 A/D (this work) 
pcDNA3.1-(His)6-EF1A1 T88A/D (this work) 
pcDNA3.1-(His)6-EF1A1 S21A/D (this work) 
pcDNA3.1-(His)6-EF1A2 S21A/D (this work) 
 
Primers: 
EF1A1 pcDNA3.1-(His)6 for 
5`-tag ctt ggt acc gag atg gga tcc gaa aag act -3` 
EF1A1 pcDNA3.1-(His)6 rev 
5`-agt ctt ttc gga tcc cat ctc ggt acc aag cta -3` 
EF1A1 pEBG for 
5`-aaa aaa gga tcc atg gga aag gaa aag act cat atc aac att gtc-3` 
EF1A1 pEBG rev 
5`-aaa aaa tct aga tca ttt  agc ctt  ctg agc ttt  ctg ggc aga ctt  -3` 
EF1A1 S21A for 
5`-gta gat  tcg ggc aag gcg acc act  act  ggc cat -3` 
EF1A1 S21A rev 
5`-atg gcc agt agt ggt cgc ctt gcc cga atc tac -3` 
EF1A1 S21D for 
5`-gta gat  tcg ggc aag gat acc act  act ggc cat-3` 
EF1A1 S21D rev 
5`-atg gcc agt agt ggt atc ctt  gcc cga atc tac -3` 
EF1A1 T88A for 
5`-agc aag tac tat gtg gcg atc att gat  gcc cca-3` 
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EF1A1 T88A rev 
5`-tgg ggc atc aat gat cgc cac ata gta ctt  gct -3` 
EF1A1 T88D for 
5`-agc aag tac tat gtg gat atc att gat  gcc cca -3` 
EF1A1 T88D rev 
5`-tgg ggc atc aat gat atc cac ata gta ctt  gct -3` 
EF1A2 S21A for 
5`-gtg gac tcc gga aag gcg acc acc acg ggc cac-3` 
EF1A2 S21A rev 
5`-gtg gcc cgt ggt ggt cgc ctt tcc gga gtc cac-3` 
EF1A2 S21D for 
5`-gtg gac tcc gga aag gat acc acc acg ggc cac-3` 
EF1A2 S21D rev 
5`-gtg gcc cgt ggt ggt atc ctt  tcc gga gtc cac-3` 
 
Kits: 
BCA-protein assay kit (Pierce), MiniPrepKit (Metabion/PeqLab), QIAGEN 
Plasmid Kit (Maxi) (QIAgen), QIAquick Gel Extraction kit (QIAgen) 
 
Buffers: 
LB (Luria-Bertani) medium  
10g/L Bacto-tryptone 
10g/L NaCl 
5g/L yeast extract 
Adjust pH to 7.5 with NaOH 
For plates, add 15 g Bacto-agar per liter and ampicillin 
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LEW buffer 
50mM NaH2PO4 
300mM NaCl 
pH 8,0 
 
Bacterial strains: 
For overexpression of recombinant proteins in E. coli, different expression 
optimized strains were used: BL21C43 and Rosetta. Cloning as well as SD 
mutagenesis included the transformation of the cloning optimized E. coli 
DH5a strain. 
 
2.1.2 Working with mammalian cells 
 
Instruments: 
Cell culture hood (Heraeus Instrument), Cell culture incubator (Heraeus 
Instrument), Light microscope (Leica), Megafuge 1.0 R (Heraeus), Mini centrifuge 
refrigerated (Eppendorf), Water bath (Kötterman) 
 
Chemicals and cell culture compounds: 
  
10xPBS (Fluka), DMEM (Gibco), L-Glutamin (Gibco), JetPEI (Polyplus-
transfection), MG132 (Calbiochem), Penicillin/Streptomycin (Gibco), 
Trypsin EDTA (Invitrogen), Ni-NTA agarose (QIAgen), Glutathion-
sepharose (Amersham), NP40 (SIGMA), Orthovanadat (SIGMA), Tris-
(hydroxymethyl)-aminomethane (Tris) (AppliChem), -glycerophosphate 
(SIGMA), Dithiothreitol (DTT) (Roth), Triton-X100 (SIGMA), Imidazole 
(SIGMA). 
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Buffers: 
Ni-NTA buffer 
100mM NaH2PO4 
10mM Tris-Cl 
pH 8,0 
Glutathion sepharose buffer: 
20mM Hepes 
150mM NaCl 
50mM Tris 
0,1% NP-40 
pH 7,5 
For washing of glutathion sepharose beads, NaCl was increased to 250mM 
 
Cell line: 
The cell line used in this study was cultured in Dulbeccos Modified Eagle 
Medium (DMEM) with 10% FCS , 2 mM L-glutamine, and antibiotics 
(penicillin-streptomycin). All works using cell culture methods were 
perfomed under a sterile bench. Cell line used was the following: COS 7 
cells (African green monkey kidney). 
 
2.1.3 Electrophoresis and Western blotting 
 
Instruments: 
Developing machine (AGFA), Electrophoresis power supply (Bio-Rad) 
Electrophoresis unit Bio-Rad Mini-Protean II, pH meter (WTW pH525), 
Spectrophotometer Ultraspec 3000 (Pharmacia Biotech) 
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Chemicals: 
Acrylamide (30%)/Bisacrylamide (0.8%), 37,5:1 (Roth), SDS (Fluka), 
TEMED (SIGMA), Ammonium peroxydisulfate (APS) (SIGMA), Glycine 
(Roth), Protein ladder (Fermentas), Bromphenolblue (SIGMA), Ponceau S 
(SIGMA), , Tween20 (SIGMA), Whatman 3MM Paper (Schleicher & 
Schüll), PROTRAN nitrocellulaose membrane (Schleicher & Schüll), Milk 
powder (AppliChem), X-ray film Super RX (Fuji), Agarose ultra pure 
(Roth), Ethidiumbromide (SIGMA), 10xTBE (tris-borate-EDTA) 
(AppliChem), 1 kb DNA ladder (Fermentas) 
 
Antibodies: 
mouse -EF1A (Upstate), mouse -HA (Santa Cruz), rabbit -GST (Santa 
Cruz), mouse -Ubiquitin (Santa Cruz), mouse -actin (Santa Cruz) mouse 
-penta-His (QIAgen). 
 
Kits: 
ECL detection kit (Amersham), ECL SuperSignal (West Pico kit Pierce) 
 
Buffers: 
10xSDS-PAGE running buffer: 
0,025M Tris 
0,25M Glycine 
1,0% SDS 
pH of 10x is 8,8 (1x buffer has pH 8,3) 
SDS-PAGE stacking-gel buffer: 
250mM Tris-HCl 
Materials and Methods 
 
27 
 
0,2% SDS 
pH 6,8 
SDS-PAGE separating-gel buffer: 
750mM Tris-HCl 
0,2% SDS 
pH 8,8 
5xLämmli sample buffer: 
31mM Tris-HCl, pH6.8 
1% SDS 
5 % Glycerin 
2.5 % -Mercaptoethanol 
0.05 % Bromphenolblue 
1xBlotting buffer: 
25mM Tris 
192mM Glycine 
15% Methanol 
10xTBST: 
500mM Tris-HCl, pH 7,4 
1,5M NaCl 
0,05% Tween20 
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2.2 METHODS 
 
2.2.1 Purification of His-tagged proteins from E. coli  
 
Recombinant proteins were overexpressed in 500 ml of appropriate E. coli 
strains (Rosetta, BL21C43) using IPTG . To prevent the formation of 
inclusion bodies during the expression of recombinant EF1A1 and EF1A2, 
the overexpression was induced at 15° C overnight and 120 rpm in a shaker. 
On the next day, the cells were centrifuged at 4000 rpm and 4°C for 20 
minutes. The supernatant was discarded and the resulting debris pellet was 
resuspended in 10 ml LEW buffer containing freshly added protease 
inhibitors (PMSF, leupeptin, aprotinin, benzamidin) and Dnase (10U/μl). 
After 30 min incubation at 4°C the cells were sonicated 45 sec with bursts 
of 1 sec. The lysed cells were centrifuged at 15000 rpm at 4°C for 30 min. 
The protein containing supernatant was added to the equilibrated (with 2 ml 
of the corresponding LEW buffer) Protino Ni-IDA column. After draining, 
the column was washed two times with 2 ml washing buffer (containing 10 
mmol, 20 mmol immidazol, respectively). The bound recombinant protein 
was finally eluted 4 times with 1,5 ml elution buffer (containing 50 mmol, 
100 mmol, 180 mmol, 200 mmol immidazol). The samples were mixed with 
glycerol and frozen at -20° C for further investigations. Successful 
purifications were analyzed by Comassie blue staining and/or 
immunoblotting.  
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2.2.2 In vitro Kinase assay 
 
In general, kinases bind and hydrolyse ATP into ADP + P. The transfer of 
the free phosphate group to their substrate protein results in a 
conformational change of these proteins. This phosphorylation reaction is 
restricted to exponated amino acids on the substrate protein. In the case of 
tyrosine kinases a tyrosine whereas in the case of a serine/threonine kinase a 
serine and/or a threonine on the target protein is phosphorylated. The 
interaction depends on the ratio between kinase and substrate and potentially 
other participating proteins (e. g. scaffolding proteins) or post-translational 
modifications (e. g. ubiquitination etc.). An in vitro kinase assay renders the 
above described biochemical kinase/substrate interaction. To test the 
activity of kinases as well as of substrates, recombinant proteins, purified 
from SF9 cells or E. coli, were used. Depending on the kinase and the 
substrate, recombinant proteins were mixed in a 1:3 to 1:5 ratio ensuring a 
substrate excess. Further components were added as indicated below. 
 
Component Volume in μl Final Concentration 
 
Kinase Variable Approx. 300 ng 
Substrate Variable Approx. 900 – 1500 ng 
10 x Kinase Buffer 3 1 x 
ATP* 3-100 μmol 
DTT 1 1 mM 
MgCl2 1-10 mM 
ddH2O ad final volume 30 l 
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*In the case of radioactive labelling, 5 - 10 μCi [32P] ATP, corresponding 
to 0,5 – 1,0 μl, are added. The mixture was incubated at 37°C and 600 rpm 
for 1 h on a thermomixer. The reaction was stopped by addition of 4 x 
Laemmli buffer to a final 1 x concentration and analyzed by 
immunoblotting with phosphospecific antibodies or, in case of radioactive 
labelling, preposition of the nitrocellulose membrane to an X-ray film at -
80° C overnight. 
 
2.2.3 Mass Spectrometry Measurements 
 
Samples were separated
 
by SDS-PAGE using NuPAGE Novex 4-12% Bis-
Tris gels (MOPS buffer
 
system). Gels were subjected to silver staining, and 
the
 
respective bands were excised and washed according to Shevchenko
 
et 
al.. Briefly, gel pieces were washed 3 times alternately
 
with 50 µl of 50 mM 
NH4HCO3 and 25 mM NH4HCO3 in 50% acetonitrile.
 
Subsequently, the gel 
slices were dried in a vacuum centrifuge.
 
5 µl of trypsin solution (12.5 ng/µl 
in 50 mM ammonium
 
bicarbonate) were added to each gel piece and 
incubated at 37
 
°C overnight for in-gel digestion. The obtained peptides
 
were eluted with 20 µl of 5% formic acid and subjected
 
to nano-liquid 
chromatography-MS/MS analysis. Thereby, an Agilent 1100 nano-HPLC 
system (Agilent Technologies GmbH, Boeblingen, Germany) was used.
 
The 
samples were preconcentrated on a 100-µm inner diameter,
 
2-cm C18 
column (nanoseparations, Nieuwkoop, The Netherlands)
 
using 0.05% 
trifluoroacetic acid with a flow rate of 8 µl/min.
 
The peptides were then 
separated on a 75-µm inner diameter,
 
15 cm, ZorbaxSB300-C18-column 
(flow rate 300 µl/min; Agilent Technologies GmbH, Boeblingen, Germany) 
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using a 2-h binary gradient from 5 to
 
50% solvent B (solvent A: 0.2% 
formic acid; solvent B: 0.2%
 
formic acid, 84% acetonitrile). The nano-
HPLC was directly coupled
 
to a QTOF-mass spectrometer (QStar XL, 
Applied Biosystems
 
GmbH, Darmstadt, Germany) acquiring repeatedly one 
full-MS and
 
two tandem-MS spectra of the most intensive ions in the 
respective
 
full MS scan. The tandem-MS spectra were searched against the
 
NCBInr data base using the Spectrum Mill software
 
(Rev A.03.03.080 SR1; 
Agilent Technologies GmbH, Boeblingen, Germany) using the following
 
adjustments: taxonomy (Homo sapiens), trypsin as protease, one
 
missed 
cleavage site, oxidation of methionine, phosphorylation of serine, threonine 
and tyrosine, pyroglutamic
 
acid for N-terminal Gln as variable 
modifications, 0.2-Da tolerance
 
for MS and MS/MS signals, and only 
doubly and triply
 
charged ions. 
 
2.2.4 Site Directed Mutagenesis 
 
Specific mutations at a single nucleotide in a DNA sequence are introduced 
via site directed mutagenesis. For this PCR reaction each oligonucleotide 
(forward and reverse) consists of in total 11 base triplets. 10 of those base 
triplets are complementary to the parental strand, whereas the sixth base 
triplet contains the point mutation which should be introduced into the 
vector. The amplification of the complete insert containing vector is carried 
out by a Pfu polymerase (stratagene, metabion, respectively) with a 3'-5' 
exonuclease activity (proof reading activity) providing a low error rate. 
Following amplification, the SD mutagenesis product is treated with the 
Dpn I endonuclease (1 hour at 37°C plus inactivation for 30 minutes at 
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80°C) specifically digesting the methylated parental DNA strand. Thus, the 
final product theoretically consists mainly of daughter strands that contains 
the desired mutation. SD mutagenesis was performed according to the 
following PCR program: 
 
Standard PCR program for amplification of DNA 
Step Temperature Time Cycle(s) 
 
Denaturing 95°C 3 min 1 
Denaturing 95°C 0,5 min 
Annealing TM-3-5°C 0,5 min 
Elongation 72°C variable min* 
Completion 72°C 10 min 1 
Storage 4°C hold  
*The duration of the elongation cycle depends on the total length of the 
vector and was calculated based on the processivity of the average Pfu 
polymerase (2 min per 1000 bp) 
 
2.2.5 Transformation of competent bacteria 
 
Thaw frozen bacteria on ice and add at least 0,5 μg/μl DNA to 100 μl 
competent bacteria. Gently mix the solution and place it on ice for 30 min. 
Incubate the cells at 42°C for 50 sec and place them on ice for 30 min. Add 
1 ml room temperatured LB media and incubate the bacteria at 37°C and 
1000 rpm on a mixer. Centrifuge the cells at 11.000 rpm, invert the tube to 
discard the supernatant and resuspend the cells in 100 μl LB-media. Plate 
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the cell suspension on a LB agarplate (containing antibiotics for selection) 
and incubate at 37° C overnight. The selected colonies are transformed with 
DNA according to the encoded resistence on the plasmid. 
 
2.2.6 Isolation of plasmid DNA 
 
For the isolation of plasmid DNA 2 ml of a 5 ml overnight culture is used. 
The plasmid is prepared according to the manufacturer`s instructions of the 
Miniprep Kit from met@bion or PeqLab based on the alkaline lysis of 
bacterial cells (Birnboim and Doly, 1979). For the transfection of 
mammalian cells, DNA is prepared from 200 ml of overnight cultured 
bacteria according to the manufaturer`s protocol of the Maxi Prep Kit 
(QIAgen). In general, contaminating proteins, lipids and chromosomal DNA 
are precipitated, whereas the auqeous plasmid DNA is bound on a silica 
matrix in the presence of high salt. 
 
2.2.7 Transfection and lyses of mammalian cells 
 
For overexpression of proteins in mammalian cells, cells are transfected 
with JetPEI solution  according to the manufacturer`s protocol. In general, 
transfected cells are harvested 48 h after transfection by cell scraper in 
1xPBS. Harvested cells are washed two times with 1ml 1xPBS (centrifuge 
each time at 2000 rpm for 2 min). After the final centrifugation step, the cell 
pellet is either lysed immediately or frozen at -80° C. 
For lysis, cells are resuspended in lyses buffer (1ml/2x10
6
 cells) containing 
freshly added protease inhibitors and rotated at 4°C for 30 min. Afterwards 
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cell debris is pelleted by centrifugation at 13.200 rpm and 4°C for 30 min. 
The protein containing supernatant is transferred into a new reaction tube 
for following experiments or frozen at -20°C. 
 
2.2.8 Pull down of GST - or His – tagged Proteins 
 
Depending on the tag of the recombinant protein, a glutathion - / Ni - matrix 
based isolation of in mammalian cells overexpressed tagged proteins has 
been performed. For this purpose, the cells are lysed as described above. 
According to the manual, protein amounts were quantified with protein 
detection kit. Equal protein amounts were bound on pre-equilibrated beads 
and the desired protein is bound to the matrix via incubation of 2 hours at 
room temperature (RT) or overnight (ON) at 4°C . The bound protein is 
washed 2 times (centrifugation for 2 min at 2000 rpm and 4° C) in 1 ml of 
an appropriate buffer by inverting the reaction 6 – 8 times. For the final 
washing step (centrifugaton for 2 min at 2000 rpm and 4° C), the buffer 
contains 20 mM freshly added immidazole or, in case of glutathion 
sepharose up to 250 mM NaCl, reducing to the matrix unspecifically bound 
proteins. 100 μl of the appropriate eluition buffer as well as 50 μl 4 x 
Laemmli buffer are added to the beads and, in the last case, the mixture is 
heated for 5 min at 100° C.  
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3. RESULTS 
Previous experiments showed in vivo an interaction between the elongation 
factor 1A and C-Raf kinase during a survival response, mediated by the 
RAS/Erk pathway, and induced by the EGF-R during treatment of the 
human epidermoid cancer cell line H1355 with IFN. In particular this 
interaction resulted in a phosphorylation of EF1A that seems to be involved 
in the upregulation of its protein levels.  
 
3.1 Purification of recombinant EF1A1 and EF1A2 from E.Coli 
 
In order to identify the sites on EF1A that are involved in RAF kinase 
mediated phosphorylation, both EF1A isoforms were expressed and purified 
from E. Coli according to the procedure described in the methods section. 
After the cell lysis, the protein purification was performed using a Ni-IDA 
matrix and the fractions were analyzed by SDS-PAGE. As reported in Fig. 
3.1 A, the elution profile revealed that fraction 2 was, in all preparations, the 
most suitable for the following phosphorylation experiments. The presence 
of EF1A was also confirmed by immunoblotting with antibody anti-EF1A 
(Fig. 3.1 B). Data related to the purification of EF1A2 are not shown. 
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Fig. 3.1 EF1A1 His-Tag purification. A) Comassie staining and B) Western blotting 
analysis with Ab anti-His of the elution fractions.  Lanes: 1, size marker; 2, lysate; 3, pellet; 
4, supernatant; 5, 6, 7, washes; 8, 9, 10, 11, elution fractions 
 
3.2 B-RAF but not C-RAF phosphorylates EF1A1 and EF1A2 in vitro 
 
Purified recombinant EF1A1 and EF1A2 from E. Coli were used to perform 
in vitro kinase assays in presence of [-32P]ATP and recombinant B-RAF 
(B-RAF wt or constitutively active B-RAF mutant V600E*) as well as C-
RAF (constitutively active C-RAF DD) purified from Sf9 cells. C-RAF 
K75D and B-RAF K75D** were used as negative controls. After the 
phosphorylation reaction, samples were separared by SDS-PAGE and 
transferred on a nitrocellulose membrane that was exposed to a X-ray film at 
-80°C over night. The autoradiography (Fig. 3.2) showed that B-RAF wt 
and the constitutively active B-RAF mutant V600E were able to 
phosphorylate both, EF1A1 and EF1A2 (Fig. 3.3) in vitro. C-RAF instead, 
did not show any phosphorylation activity on both EF1A isoforms. 
*Constitutively active B-RAF mutant V600E is a more active form of the kinase in which 
the exchange of valine against glutamate create a negative charge that mimics the 
phosphate group  
** C-RAF K75D and B-RAF K75D are kinases with a negatively modified amino acid in 
the ATP binding pocket  
      
72 
55 
43 
kDa 
EF-1A--(His) 
6 
anti-His AB  
1     2      3      4      5      6      7     8      9     10    11 
A 
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Fig. 3.2 In vitro kinase assay of EF1A1. A) Autoradiography. B), C) and D) 
Immunoblotting against antibody anti EF1A, B-RAF and C-RAF, respectively. EF1A1 wt 
was incubated in presence of B-RAF wt, B-RAF V600E and C-RAF DD, respectively. 
Lanes: 1, B-RAF wt (diluted 1:5) + EF-1A1 wt; 2, B-RAF wt + EF-1A wt; 3, B-RAF 
V600E (diluted 1:5) + EF-1A1 wt; 4, B-RAF V600E + EF-1A1 wt; 5, B-RAF wt; 6, EF-
1A1 wt; 7, B-RAF wt + MEK + ERK; 8, C-RAF DD + EF-1A1 wt; 9, C-RAF K75W + EF-
1A1 wt; 10, B-RAF K75W + EF1A1 wt. 
 
 
 
 
 
 
 
 
Fig. 3.3  In vitro kinase assay of EF1A2. EF1A2 wt was incubated in presence of  
B-RAF wt and C-Raf DD, respectively. Lanes: 1, B-RAF wt + EF-1A2 wt; 2, B-
RAF wt; 3, B-RAF wt + MEK + ERK; 4, C-RAF DD + EF-1A2 wt; 5, C-RAF DD; 
6, C-RAF DD + MEK + ERK. 
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3.3 Reduction of B-RAF activity on EF1A1 mutated in the predicted 
phosphorylation sites 
 
Combining in silico molecular modelling and molecular dynamic 
simulation, putative EF1A serines and threonines were predicted as 
phosphorylation sites (Lamberti et al., 2007). 
Based on this analysis and considering the sites with the highest probability, 
mutants of EF1A1 (S18A, S157A, T242A, S316A, S383A and T432A) 
were generated in order to verify their involvement in the RAF kinases 
mediated phosphorylation. To this purpose, an in vitro kinase assay, as 
above described, was performed. After exposure of the membrane to the X-
Ray film, it was found that, with respect to EF1A wt, the B-RAF mediated 
phosphorylation of EF1A1 appeared to be reduced only for the EF1A1 
single mutant T432A and S316A (Fig. 3.4 A). Densitometric evaluation of 
band intensity revealed a reduction of 62.2 and 63.4 % for the T432A 
mutant and the S316A mutant, respectively (Fig. 3.4 B). 
To assess if the contemporary presence of both mutations would have 
further reduced the phosphorylation signal previously observed, the double 
mutant S316A/T432A was generated, purified and assayed for 
phosphorylation as already described. As reported in Fig. 3.5, compared to 
EF1A wt, the extent of the phosphorylation signal observed was reduced 
also for the double mutant. 
To exclude the involvement of a Mek homologue, possibly present as a 
contaminant in the B-RAF preparation from Sf9 cells, B-RAF wt and 
EF1A1 wt were incubated in presence of Mek inhibitor U0126 (Fig. 3.5). 
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Densitometric evaluation of band intensity revealed a reduction of 73.1 and 
57.5 % for the double mutant and EF1A1 wt in the presence of U0126, 
respectively (Fig. 3.5 B).  
 
 
 
 
 
Fig. 3.4 In vitro kinase assay of EF1A1 mutants. A) Autoradiography. The kinase assay 
was performed incubating B-RAF wt in the presence of EF1A1 wt (lane 1) and EF1A1 
mutants T242A (lane 2), S18A (lane 3), S157A (lane 4), T432A (lane 5), S316A (lane 6) 
and S383A (lane7), respectively. B) Densitometric evaluation.  
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Fig. 3.5 In vitro kinase assay on EF1A1 wt and double mutant. A) Autoradiography. B) 
and C) immunoblotting against B-RAF and EF1A antibodies, respectively. The kinase 
assay was performed incubating B-RAF wt in presence of EF1A1 wt (lane 1), EF1A1 
S316A/T242A (lane 2), respectivly, The assay was also performed in the presence of MEK 
inhibitor U0126 (lane 3). D) Densitometric evaluation. 
 
 
3.4 Phosphorylation of a potential EF1A heterodimer by C-RAF in vitro 
 
In precedent in vitro experiments it was found that C-RAF was not able to 
phosphorylate EF1A1 as well as EF1A2, contrary to what previously 
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phosphorylate a potential EF1A heterodimer in vitro, EF1A1 and EF1A2 
were mixed, preincubated in the kinase buffer for 10 min and then assayed 
for phosphorylation by the addition of C-RAF DD kinase. The results 
obtained showed the presence of a phosphorylation signal corresponding to 
the size of EF1A (Fig. 3.6 A). This correspondence was confirmed by 
probing the same membrane with anti-His Ab (Fig. 3.6 B). 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6 C-RAF DD kinase assay of EF1A1 and EF1A2. A) Autoradiography; B) Anti-
His antibody detection. Lanes: 1, positive control; 2, C-RAF DD + EF1A1 + EF1A2; 3, C-
RAF DD. 
 
 
3.5 Identification of phosphorylation sites on EF1A1 and EF1A2 
mediated by RAF kinases in vitro 
 
To identify the amino acid residues of EF1A involved in the RAF-mediated 
phosphorylation, equal amounts of EF1A1 and EF1A2, alone or together, 
were incubated with either B-RAF or C-RAF in the presence of cold ATP 
and analyzed by mass spectrometry. Analysis of the phosphopeptides 
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indicated that in presence of B-RAF, EF1A1 was phosphorylated at residues 
Serine 21 and Tyrosine 86 or Threonine 88 and EF1A2 at residue Serine 21. 
In the presence of C-RAF, EF1A2 was phosphorylated at residue of Serine 
21. No data was collected for the C-RAF mediated phosphorylation of 
EF1A1. When the assay was performed on both isoforms, EF1A1 and 
EF1A2 were phosphorylated on Serine 21 either in the presence of B-RAF 
or C-RAF (Table  1). 
 
Table 1. Identified phosphorylation sites on EF1A1 and EF1A2 
 
Kinases Substrates Phosphorylated sites 
B-RAF EF1A1 S21, Y86/T88 
B-RAF EF1A2 S21 
B-RAF EF1A1 + EF1A2 S21; S21 
C-RAF EF1A1 n.d. 
C-RAF EF1A2 S21 
C-RAF EF1A1 + EF1A2 S21; S21 
 
 
3.6 Purification of EF1A1 wt and EF1A2 wt expressed in COS 7 cells  
 
EF1A1 and EF1A2 were cloned in mammalian expression vectors (pEBG 
and pCDNA 3.1, respectively) and expressed in COS 7 cells, in order to 
determine if post-translational modifications, normally not occurring in the 
E. coli heterologous expression system, could influence the in vitro 
phosphorylation of EF1A mediated by RAF kinases. Because of the lack of 
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a specific antibody raised against the two isoforms, EF1A1 was fused to 
GST whereas EF1A2 was provided with a His-Tag. 48h after transfection, 
the cells were harvested and GST-EF1A1 was purified from the lysate using 
glutathione sepharose. The SDS-PAGE of purified proteins (Fig. 3.7) 
showed the presence of a stained band of about 72 kDa, corresponding to 
the size of EF1A1 (46 kDa) plus GST (26 kDa). A similar result was 
obtained for the purification procedure of EF1A2-His (about 52 kDa, data 
not shown). 
 
 
 
Fig. 3.7 Purification of EF1A1 wt GST-Tag. Comassie staining of the purification 
procedure: lysate and supernatant (lanes 1 and 2), washes (lanes 3, 4, 5), elutions (lanes 6, 
7, 9), size marker (lane 8). GST-EF1A1 corresponds to the band around 72 kDa.  
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3.7 Identification of phosphorylation sites and interaction partners of 
EF1A1 expressed in COS 7 cells 
 
EF1A1 wt fused to GST was expressed in COS 7 cells and purified 
according to the procedure described above. The purified GST-EF1A1 was 
extracted from the silver stained SDS-PAGE gel and analysed by mass 
spectrometry. The phosphopeptides obtained after tryptic digestion of the 
protein, led to the identification of two phosphorylation sites on EF1A1 
(Table 2). These sites were coincident with those found in the previous mass 
spectrometry analysis performed on recombinant EF1A1 purified from E. 
Coli after the in vitro kinase assay in the presence of B-RAF (Tab. 3).  
 
Tab. 2. Phosphorylation sites identified on EF1A1 expressed in COS 7 cells 
 
Phosphopeptide sequence Modified aa residues 
K.YYVpTIIDAPGHRDFIK.N T 88 
K.p(YY)VTIIDAPGHR.D Y 86 
 
Moreover, silver staining of the SDS-PAGE gel revealed the presence, in 
comparison to the GST control (not shown), of several additional bands that 
were also analysed by mass spectrometry (Fig. 3.8). The proteins identified 
are listed in Table 3. These include all components of the protein synthesis 
elongation cycle, heat shock proteins (HSP), laminin, polyadenylate binding 
protein 1and Peroxiredoxin-1. These finding are in line with the already 
known literature data (Bohnsack et al., 2002; Khacho et al., 2008; Marchesi, 
1993; Chang et al., 2006). 
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Fig. 3.8 Interaction partners of EF1A1 expressed in COS 7 cells. Silver staining of the 
SDS-PAGE gel. 1) Size Markers; 2) Proteins identified in the elution of GST pull down 
experiment. The number is referred to the proteins identified that are reported in Table 3. 
 
 
Table 3. EF1A1 interaction partners identified after GST pull-down 
 
Band 
 
Accession N. 
 
Protein Sequence coverage 
(%) 
1 IPI00396485 EEF1A1 Elongation factor 1-alpha 1 64 
1 IPI00007765 HSPA9 Stress-70 protein, mitochondrial 56 
1 IPI00003865 
HSPA8 Isoform 1 of Heat shock cognate 
71 kDa protein 47 
1 IPI00003362 HSPA5 HSPA5 protein 41 
1 IPI00021405 LMNA Isoform A of Lamin-A/C 14 
1 IPI00008524 
PABPC1 Isoform 1 of Polyadenylate-
binding protein 1 13 
1 IPI00414676 
HSP90AB1 Heat shock protein HSP 90-
beta 7 
2 IPI00747497 EEF1G 50 kDa protein 28 
2 IPI00396485 EEF1A1 Elongation factor 1-alpha 1 18 
3 IPI00023048 EEF1D Elongation factor 1-delta 24 
4 IPI00178440 EEF1B2 Elongation factor 1-beta 8 
5 IPI00178440 EEF1B2 Elongation factor 1-beta 18 
6 IPI00219757 GSTP1 Glutathione S-transferase P 21 
6 IPI00000874 PRDX1 Peroxiredoxin-1 13 
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3.8 Purification of EF1A1 mutants expressed in COS 7 cells  
 
To study the effect of the B-RAF and C-RAF mediated phosphorylation on 
EF1A, recombinant EF1A1 and EF1A2, already cloned in a mammalian 
vector (pEBG and pCDNA 3.1, respectively), were mutated in the positions 
Serine 21 and Threonine 88 on EF1A1 and Serine 21 on EF1A2. To mimic 
the negative charge of the phosphate group, Serine/Threonine was replaced 
by Glutamate (dominant positive), whereas the exchange of 
Serine/Threonine against Alanine prevents the phosphorylation on these 
sites (dominant negative). These proteins were expressed in COS 7 cells and 
purified by GST pull-down. As reported in Fig. 3.9, the proteins are 
expressed in COS 7 cells at different levels. In particular, the S21A and 
S21D mutants seem to be less expressed compared to EF1A1 wt as well as 
T88A and T88D EF1A1 mutants. These results suggest that these proteins 
are in vivo less stable and that the RAF kinase mediated phosphorylation of 
S21 might play a regulatory role affecting EF1A1 expression levels. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.9 Purification of EF1A1 wt and mutants from COS 7 cells. Comassie staining of 
the SDS-PAGE. Lanes: SM, size markers; 1 and 2, elution fractions of EF1A1 wt; 3 and 4, 
elution fractions of S21A; 5 and 6, elution fractions of S21D; 7 and 8, elution fractions of 
T88A; 9 and 10, elution fractions of T88D. 
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3.9 Stability of the S21 mutants of EF1A1 and EF1A2 in vivo  
 
To compare the stability of the S21 mutants of EF1A1 with those of EF1A2 
in vivo, the expression levels of both EF1A isoforms were evaluated. To this 
purpose, EF1A1 was cloned in the mammalian vector pCDNA 3.1 and 
expressed as His-EF1A1 in COS 7 cells. 36 h after transfection, cells were 
harvested and lysed. Following the His pull-down, the protein samples were 
analysed by immunoblotting with anti-His antibody. As reported in Fig. 
3.10, compared to EF1A1 wt and EF1A2 wt, the expression of S21 mutants 
of EF1A1 and EF1A2 appear negatively regulated in vivo. In particular, the 
S21 mutants of EF1A2 seem to be more sensitive to this regulation. 
 
 
 
Fig 3.10 Immunoblotting of EF1A1 and EF1A2 protein expression levels in COS 7 
cells. COS 7 cells, after transfection, were analysed for EF1A1 expression with antibody 
anti-His. A) Cell lysate, B) pull-down. Lanes: 1, EF1A1 wt; 2, S21A; 3, S21D; 4, T88A; 5, 
T88D. COS 7 cells, after transfection, were analysed for EF1A2 expression with antibody 
anti-His. C) Cell lysate, D) pull-down. Lanes: 1, EF1A2 wt; 2, S21A; 3, S21D. 
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3.10 Ubiquitination and stability of EF1A1 wt, EF1A2 wt and their 
mutants in vivo  
 
The above results revealed different expression levels of EF1A1 and EF1A2 
mutants suggesting an ubiquitin-dependent degradation of these mutated 
enzymes. Therefore, to better evaluate the stability of EF1A1 wt, EF1A2 wt 
and their mutants as well as their endogenous ubiquitination, COS 7 cells 
were transfected with the EF1A1 and EF1A2 constructs for 36 h and 
subsequently incubated in the presence or absence of MG 132 for 12 h. 
Immunoblotting analysis with anti-His antibody of the cell extracts and 
corresponding His-pull-down samples showed that compared to EF1A1 
(Fig. 3.11 A and 3.11 B) also for the EF1A2 mutants, the polyubiquitination 
level was higher than that of EF1A2 wt (Fig. 3.11 C and Fig. 3.11 D). To 
compare the level of the endogenous ubiquitination with that observed when 
also ubiquitin was co-expressed, COS 7 cells were cotransfected with 
EF1A1 and EF1A2 constructs and ubiquitin wt for 36 h and then incubated 
in the presence or absence of the proteasome inhibitor for 12 h. As reported 
in Fig. 3.12, also in these cases, the polyubiquitination levels of EF1A1 wt 
and EF1A2 wt appeared lower than the corresponding mutants. 
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Fig 3.11 Immunoblotting after pull-down of the endogenous ubiquitination of EF1A1 
and EF1A2 and their mutants. After cotransfection and treatment of cells in the absence 
(-) or in the presence (+) of MG132, cell extracts were analysed before and after pull-down 
for EF1A1 and EF1A2, respectively by immunoblotting with antibody anti-His. EF1A1: A) 
lysates, B) pull-down. Lanes: wt, EF1A1 wt; 1, EF1A1 S21A; 2, EF1A1 S21D; 3, EF1A1 
T88A; 4, EF1A1 T88D. EF1A2: C) lysates, B) pull-down. Lanes: wt, EF1A2 wt; 1, EF1A2 
S21A; 2, EF1A2. 
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Fig 3.12 Immunoblotting after pull-down of the ubiquitination of EF1A1 and EF1A2 
and their mutants. After cotransfection with ubiquitin wt and treatment of cells in the 
absence (-) or in the presence (+) of MG132, cell extracts were analysed before and after 
pull-down for EF1A1 and EF1A2, respectively by immunoblotting with antibody anti-His. 
EF1A1: A) lysates, B) pull-down. Lanes: wt, EF1A1 wt; 1, EF1A1 S21A; 2, EF1A1 S21D; 
3, EF1A1 T88A; 4, EF1A1 T88D. EF1A2: C) lysates, B) pull-down. Lanes: wt, EF1A2 wt; 
1, EF1A2 S21A; 2, EF1A2. 
 
 
 
 
 
 
 
 
 
 
 -     +     -      +     -     +     -     +     -     +
wt          1            2            3           4
A
B
EF1A1
-        +      -         +       -       +
wt               1                 2       
EF1A2
C
D
EF1A1 EF1A2
47.5 47.5
47.547.5
62
kDA kDA
62
62
Results 
 
51 
 
To confirm that reduced expression of EF1A1 and EF1A2 mutants was 
ascribed to a reduced stability of the proteins i.e. to an increase of their 
ubiquitination and thus to proteasome-dependent degradation, the same 
EF1A samples were cotransfected with ubiquitin K48* or ubiquitin wt for 
36 h followed by subsequent incubation of transfected cells for 12 h with the 
proteasome inhibitor MG 132. Cell extracts were then analysed by pull 
down with glutathion sepharose or a Ni-NTA matrix for EF1A1 and EF1A2 
expression, respectively, and the membranes were subsequently probed with 
antibody anti-His to reveal the level of EF1A and anti-HA to detect HA-
ubiquitin K48 (Fig. 3.13). As reported in Fig 3.13 A, the inhibition of the 
proteasome by MG 132 led to an accumulation of polyubiquitinated proteins 
that, compared to EF1A1 wt, was higher for the EF1A1 mutants (Fig. 3.13 
B). Regarding EF1A2 and its mutants, the protein levels, immunodetected 
after pull-down showed that also for the EF1A2 mutants, the 
polyubiquitination level was higher than that of EF1A2 wt (Fig. 3.13 C). 
Thus, either if the transfection was done with HA-ubiquitin K48 or HA-
ubiquitin wt, the polyubiquitination levels appeared quite similar. These 
results indicate that in the presence of the proteasome inhibitor, although at 
different extents, all EF1A1 and EF1A2 mutants appeared to be more 
polyubiquitinated than the corresponding wild type factors. This suggests 
that the instability of the expressed mutants is due to a more rapid 
degradation mediated by the proteasome. 
 
*Ubiquitin K48. A mutant that can only form K48-branched ubiquitin chains. 
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Fig. 3.13 Immunoblotting after pull-down of the ubiquitination of EF1A1 and EF1A2 
and their mutants: after cotransfection with either ubiquitin K48 or ubiquitin wt and 
MG132 treatment, cell extracts were analysed after pull-down for ubiquitination of EF1A1 
and EF1A2, respectively by immunoblotting with antibody anti-His and anti-HA. A) and B) 
EF1A1. Lanes: 1 EF1A1 wt + UB HA K48; 2, EF1A1 S21A + UB HA K48; 3, EF1A1 
S21D + UB HA K48; 4, EF1A1 T88A + UB HA K48; 5, EF1A1 T88D + UB HA K48; 6, 
UB HA K48; 7, EF1A1 wt; 8, UB HA wt; 9, EF1A1 wt + UB HA wt; 10, EF1A1 S21A  + 
UB HA wt; 11, EF1A1 S21D + UB HA wt; 12, EF1A1 T88A + UB HA wt; 13, EF1A1 
T88D + UB HA wt. C) EF1A2. Laned 1, EF1A2 wt + UB HA k48; 2, EF1A2 S21A + UB 
HA k48; 3, EF1A2 S21D + UB HA k48; 4, EF1A2 wt; 5, EF1A2 wt + UB HA wt; 6, 
EF1A2 S21A + UB HA wt; 7, EF1A2 S21D + UB HA wt. 
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3.11 Heterodimerization of EF1A1 and EF1A2 in vivo: preliminary 
experiments 
 
Previous in vitro experiments (section 3.4) showed a potential 
heterodimerization of both elongation factor isoforms. To further investigate 
on this potential heterodimerization in vivo, recombinant GST-EF1A1 wt 
and its mutants were cotransfected in different combination with His-EF1A2 
wt and His-EF1A2 S21D in COS 7 cells. After 24 h, the cells were 
harvested and lysed. GST-EF1A1 and associated proteins were isolated via 
GST pull-down and the resulting eluates were blotted and probed against 
antibody anti the corresponding tags of the recombinant proteins (GST and 
His). As shown in figure 3.14, all samples revealed an interaction between 
the two isoforms thus confirming in vivo the heterodimerization observed in 
vitro. In general, the overexpression of EF1A2 wt positively affects the 
stability of the heterodimerzation with EF1A1 wt and mutants (Fig. 3.14, 
lanes 1-3) compared to the overexpression of EF1A2 S21D (lanes 4-6). This 
observed increase in complex stability is enhanced in the case of EF1A1 
T88D overexpressing cells (lane 3 compared to lane 1). In contrast, the 
overexpression of EF1A2 S21D seems to reduce the complexes stability 
(lanes 3-6). In particular, overexpression of EF1A2 S21D seems to have two 
different outcomes: negatively affecting the complex formation and the 
stability of EF1A1 wt.  
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Fig. 3.14 Heterodimerization of EF1A1 and EF1A2 in vivo. EF1A1-GST and the 
indicated mutants were co-expressed in COS 7 cells with EF1A2-His wt and EF1A2-His 
S21D. EF1A1-GST and interacting proteins were isolated via GST pull down and analysed 
by immunoblotting with anti-GST and anti-His antibody. 
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4. DISCUSSION 
 
In this study, it has been examined the involvement of the translation 
elongation factor 1A isoforms in post-translational modifications induced by 
their interaction with RAF kinases. In addition, it has been evaluated if the 
phosphorylation of EF1A could also modulate its proteasome-dependent 
degradation and its GDP/GTP binding activity. This work plan was started 
on the basis of preliminary results here summarized: following treatment of 
a human hepidermoid cancer cell line (H1355) with interferon alpha (INF), 
it was observed 1. anti-apoptotic role of EF1A2 isoform; 2. phosphorylation 
of EF1A (indirectly?) mediated by C-RAF kinase, following activation of a 
survival pathway induced by EGF receptor. 
Therefore, the first aims included the determination of the specific EF1A 
proteins’ amino acid residues (EF1A1 or EF1A2) phosphorylated by RAF 
isoforms using proteomic strategies. To this purpose, recombinant EF1A1 
and EF1A2 were expressed and purified from E. coli (Fig. 1.1) and 
radioactively assayed in presence of B-RAF or C-RAF. In these conditions, 
B-RAF but not C-RAF was able to phosphorylate the EF1A1/2 isoforms 
(Fig. 1.2) whereas the result regarding the C-RAF mediated phosphorylation 
did not show an evident signal. 
 
4.1 The heterodimerization of EF1A1/2 enhances a RAF isoform 
specific phosphorylation of EF1A  
 
While both isoforms (solely) were phosphorylated by B-RAF in vitro, a 
phosphorylation of a potential EF1A heterodimer by C-RAF in vitro was 
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observed. This finding indicates that the RAF specific phosphorylation of 
the elongation factor might depend on the formation of EF1A1EF1A2 
complex. Thus it is possible that this heterodimerization enhances the 
activity of C-RAF on EF1A. This notion is underlined by the finding that no 
C-RAF mediated phosphorylation signal on EF1A2 alone was detected in 
the radioactive in vitro kinase assay, even though mass spectrometry 
analysis identified S21 as a phosphorylated residue in the same kinase 
assay. In the B-RAF/EF1A1 kinase assays, besides S21 also T88 was found 
to be a phosphorylated residue using mass spectrometry analysis. 
Remarkably, T88 was not identified when both isoforms were mixed 
together in the in vitro kinase assay. Mass spectrometry analysis also 
revealed the B-RAF mediated phosphorylation of T88 on overexpressed 
EF1A1 isolated from COS7 cells. Moreover, in the same sample, all 
members of the elongation factor 1 complex were found as well as the 
endogenous EF1A1 probably associated with overexpressed GST-EF1A1. A 
phospho-mimicking mutation of T88 (T88D) on EF1A1 enhances its 
activity to form a complex with EF1A2 in COS7 cells as observed in a pull-
down experiment (Fig. 3.14). Taken together, these results suggest a role for 
the B-RAF specific phosphorylation of T88 on EF1A1 affecting the 
formation of the elongation factor 1 complex as well as a 
homo/heterodimerization of EF1A participating in the complex. This is in 
accordance to structural modeling, where T88 is part of the binding region 
of EF1A involved in its association with EF1B (Andersen, et al., 2000; 
Soares et al., 2009). 
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4.2 The importance of the EF1A serine 21 site 
 
Both EF1A isoforms are phosphorylated by B-RAF and C-RAF on S21. As 
shown in the 3-D model (Fig. 4.1), this residue belongs to one of the three 
GTP/GDP binding site consensus sequences (Dever et al., 1987) and is 
almost located in the center of the GTP/GDP binding pocket. 
 
 
 
Fig. 4.1 Merge of EF1A1 and EF1A2 model structures. The model shows the position of 
the consensus sequences on both EF1A isoforms 3-D structures with particular regard to the 
position of the serine 21.  
 
Structural models of both EF1A1 and EF1A2 revealed the critical 
importance of Gly19, Lys20, Ser21, Thr22, Asn153, Lys154 and Asp156 
(all in domain I) within the binding sites for GTP/GDP ligands (Soares et 
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al., 2009). These observations were in agreement with previously performed 
mutagenesis studies in yeast (Carr-Schmid, et al., 1999, Ozturk et al., 2006). 
In fact, the Asn153Thr and Asp156Asn mutations of yeast EF1A resulted in 
dramatic reduction in translational fidelity. The guanine-binding pocket is 
highly conserved in both human variants. Thus, their differences in 
GDP/GTP preference ratios must be explained in another way. 
 
 
 
Fig. 4.2 Guanine-binding pocket in yeast and human variants. Close-up equivalent 
views of residues involved in binding of GTP/GDP: the yeast template (top left); all six 
yeast EF1A structures superposed (top right) and colored differently (see their 
corresponding PDB IDs below); human EF1A1 (bottom left); and human EF1A2 (bottom 
right). Labeled residues include: Gly19, Lys20, Ser21, Thr22, Asn153, Lys154, Asp156 
[GTP/GDP-binding residues] and Asn195 (yeast), Asn/His197 (human EF1A1/EF1A2) that 
show presence of H-bond (indicated by a yellow dashed line and distance in Å) with 
Asp156, absent in human EF1A2. (Fig. adapted from Soares et al., 2009; supplementary 
file S5) 
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Overexpression of the S21A/D mutants in COS7 cells revealed reduced 
protein levels due to the proteasomal degradation of the two EF1A mutants. 
According to models of EF1A from S. Sulfataricus (Fig. 4.3) the S20 side 
chain is linked directly to the oxygens of both phosphates of the GDP 
nucleotide (Vitagliano, et al., 2001) Therefore, the binding of the guanine 
nucleotide should be potentially prevented when this site becames 
phosphorylated by RAF kinases (personal communication, M. Masullo). 
 
 
 
 
Fig. 4.3 Schematic representation of GDP binding to SsEF1A. Serine 20 (black arrow) 
binds the - and - phosphates (yellow star) of GDP via a hydroxyl group. 
 
 
Moreover, the same region of EF1A is involved in the binding of EF1B 
and precisely, the EF1B C-terminal fragment lies mainly on domains I and 
II, with only a single contact with domain III (Andersen et al., 2000). 
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Therefore, closing the access of this site via phosphorylation for both GTP 
and EF1B could result in a conformational change that directs EF1A to 
interact with other partners leading to different functions. However, both 
overexpressed mutated isoforms (S21A, S21D) are degraded to almost the 
same extent. Thus, mutations of this site cause a severe modification that 
leads to the proteasomal degradation. This indicates that the S21 residue is a 
crucial site for the half-life of EF1A because its blockage prevents the 
protein from switching between its role in protein biosynthesis and its 
involvement in other functions. This leads to the hypothesis that RAF 
mediated phosphorylation of EF1A on S21 negatively regulates the GTP 
binding and/or nucleotide exchange of the enzyme and that this 
phosphorylation can be a regulatory switch for other functional roles of 
EF1A. Thus, RAF kinases potentially regulate the function of EF1A.  
 
4.3 Does the RAF mediated phosphorylation of EF1A regulate its ability 
to bind or bundle actin? 
 
Some years ago, it has been found in Dictyostelium S. that EF1A is an actin-
binding protein (Yang et al., 1990). Since then, several groups demonstrated 
that this function is conserved among the species from yeast (Munshi et al. 
2001) to mammals (Murray et al., 1996). Remarkably, more than 60% of 
EF1A is associated with the actin cytoskeleton and, moreover, it can bind to 
microtubules (Moore et al., 1998; Moore et al., 2000) centrosphere and the 
mitotic apparatus (Kuriyama et al., 1990). It has been shown that EF1A is 
also implicated in actin bundling and is essential for regulation of actin 
cytoskeleton and cell morphology (Stephane et al., 2005). As already 
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mentioned in the introduction section, EF1A1 is connected, directly or 
indirectly, with several other cellular processes different from the protein 
biosynthesis (Ejiri, 2002). This processes like apoptosis, transformation and 
drug resistance are mediated in some cases by the interaction of EF1A with 
other proteins connected to signaling of the cell. The regulatory mechanism 
of EF1A in these processes is still not clear but it is conceivable that the 
association of EF1A to actin is linked to these activities. Recent studies 
indicate that actin and aa-tRNA binding are mutually exclusive (Liu et al., 
1998) and that the EF1B interaction and actin bundling sites on EF1A are 
overlapping. Interestingly, mutational analysis revealed that EF1B is able to 
prevent EF1A association to actin bundles (Pittman et al., 2009). Since the 
C terminus of EF1B interacts with domain I and a distinct pocket of domain 
II of EF1A, it is likely that the RAF mediated phosphorylation on S21 
buries the interface with EF1B because of an induced conformational 
change of EF1A that leads also to the lack of the GDP/GTP exchange (Fig. 
4.4).  
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Fig. 4.4 Co-crystal structure of EF1AEF1B C terminusGDP. In green elongation 
factor 1A, in pink serine 21, in hot pink sticks GDP, in yellow the C terminus of the 
elongation factor 1BStructure reviewed by PyMol program.  
 
Remarkably, EF1A was also reported to be an activator of a PI 4-kinase that 
binds actin and increases actin bundling (Jeganathan, et al., 2008). 
Regarding this process Kurasawa and coworkers demonstrated F-actin 
bundling activity of Tetrahymena elongation factor 1A investigated with 
rabbit skeletal muscle actin. This activity depends on a binding ratio of 
EF1A to skeletal muscle F-Actin in the bundles of 1:1 (Kurasawa et al., 
1996). Ten years later, Bunai and colleagues (Bunai et al.,2006) showed, 
that EF1A of Tetrahymena bundles filamentous actin through dimer 
formation. In their experiments EF1A formed dimers that were able to 
bundle F-Actin, whereas EF1A monomers were not. Mutations of the RAF 
mediated phosphorylation sites on EF1A revealed differences in the 
formation of heterodimers and a different migration pattern. As shown in 
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Fig. 3.14, the S21 phosphorylation might be a second step after the 
heterodimerization that seems to be stabilized by the T88 modification. 
Taken together, these results allow to depict a model to partially explain the 
role of the RAF-EF1A interaction during the drug resistance process 
previously observed in H1355 cells treated with IFN. Lamberti at al., 2007 
showed that epidermoid tumor cells counteract the IFN-induced apoptosis 
through a survival pathway that involves the hyperactivation of the EGF-
dependent Ras->Erk signalling. Later it was also found that the elongation 
factor 1A is involved in this response via its overexpression and RAF 
mediated phosphorylation (Lamberti et al., 2007). Remarkably, both 
isoforms were found to be expressed and the amount of EF1A2 was 
increased during a time course following treatment with IFN untill its 
degradation in 60 minutes. As shown during the course of this work, the 
heterodimerization of both isoforms is connected to the RAF mediated 
phosphorylation. In particular, the phosphorylation on T88 seems to 
stabilize the complex as well as the protein itself. This suggests, that a RAF 
dependent heterodimerization interferes with the proteasomal degradation of 
both isoforms. Considering the increased EF1A expression levels which 
were shown to be correlated with an anti-apoptotic response, these 
observations indicate that the RAF signal dependent EF1A 
heterodimerization might be involved in the reported anti-apoptotic answer.  
In conclusion, B-RAF and C-RAF kinases, regulate the function of 
elongation factor 1A by phosphorylating both isoforms of the enzyme on a 
crucial aminoacid residue, Serine 21, important for the binding of 
GTP/GDP. B-RAF is also responsible for the phosphorylation of EF1A1 on 
Threonine 88, an exposed aminoacid residue of domain I. These 
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phosphorylations appear to stabilize the enzyme since mutations in this 
position increase the instability of the protein through an ubiquitin-mediated 
degradation mechanism that was confirmed by in vivo experiments. In 
addition, EF1A1 and EF1A2 are able to form a stable heterodimer complex 
that is strongly destabilized if the S21 of EF1A2 is mutated but not if the 
same position in EF1A1 is mutated, suggesting that the phosphorylation of 
this site occurs in a second moment, after the formation of the heterodimer. 
These data indicate that the S21 phosphorylation might represent a 
switching mechanism that directs EF1A toward different functional role 
than protein synthesis. This functional switch for the two EF1A isoforms 
could be at the root of the H1355 lung cancer cell line survival response 
during drug resistance process mediated by Ras->Erk signaling. 
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